Liposomes as immunological adjuvants and delivery systems in the development of tuberculosis vaccine: A review

10Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Liposomes are phospholipid bilayer vesicles, which are biocompatible, biodegradable and nontoxic vehicles suitable for numerous drug and gene delivery applications. In this review, we discuss the prospect of using liposome technology in the development of a vaccine for tuberculosis. Tuberculosis remains an important health problem that requires the development of an effective vaccine, especially since the only approved vaccine for it continues to be the Bacille Calmette-Geurin (BCG) one developed 100 years ago. This review focuses on the different applications of liposomes toward achieving this goal. Numerous liposomal formulations showing prospect in the research stage and in clinical trials are discussed.

Cite

CITATION STYLE

APA

Luwi, N. E. M., Ahmad, S., Azlyna, A. S. N., Nordin, A., Sarmiento, M. E., Acosta, A., … Kadir, R. (2022, January 1). Liposomes as immunological adjuvants and delivery systems in the development of tuberculosis vaccine: A review. Asian Pacific Journal of Tropical Medicine. Wolters Kluwer Medknow Publications. https://doi.org/10.4103/1995-7645.332806

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free